Literature DB >> 9171245

Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo.

Y Zhang1, C A Beck, A Poletti, J P Clement, P Prendergast, T T Yip, T W Hutchens, D P Edwards, N L Weigel.   

Abstract

The human progesterone receptor (hPR) in T47D breast cancer cells is phosphorylated on at least nine different serine residues. We have previously reported the identification of five sites; three are hormone inducible (Ser102, Ser294 and Ser345), and their phosphorylation correlates with the timing of the change in receptor mobility on gel electrophoresis in response to hormone treatment. The other two sites, Ser81 and Ser162, along with the remaining sites, are basally phosphorylated and exhibit a general increase in phosphorylation in response to hormone. With the exception of Ser81, all of these sites are in Ser-Pro motifs, suggesting that proline-directed kinases are responsible for their phosphorylation. We now report that cyclin A-cyclin-dependent kinase-2 complexes phosphorylate hPR-B in vitro with a high stoichiometry on three sites that are authentic basal sites in vivo. One of these is Ser162, which has been described previously. The other two sites are identified here as Ser190 and Ser400. The specificity and stoichiometry of the in vitro phosphorylation suggest that hPR phosphorylation may be regulated in a cell cycle-dependent manner in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9171245     DOI: 10.1210/mend.11.6.0006

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  35 in total

Review 1.  Modulating nuclear receptor function: may the phos be with you.

Authors:  D Shao; M A Lazar
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

2.  ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells.

Authors:  Christy R Hagan; Tarah M Regan; Gwen E Dressing; Carol A Lange
Journal:  Mol Cell Biol       Date:  2011-04-25       Impact factor: 4.272

3.  Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome.

Authors:  C A Lange; T Shen; K B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 4.  Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity.

Authors:  Nicole L Moore; Ramesh Narayanan; Nancy L Weigel
Journal:  Steroids       Date:  2007-01-04       Impact factor: 2.668

Review 5.  Integration of progesterone receptor action with rapid signaling events in breast cancer models.

Authors:  Carol A Lange
Journal:  J Steroid Biochem Mol Biol       Date:  2007-09-14       Impact factor: 4.292

6.  The requirement for p42/p44 MAPK activity in progesterone receptor-mediated gene regulation is target gene-specific.

Authors:  Lindsey S Treviño; William E Bingman; Dean P Edwards; Weigel Nl
Journal:  Steroids       Date:  2013-02-01       Impact factor: 2.668

7.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

8.  Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400.

Authors:  Suzanne E Wardell; Ramesh Narayanan; Nancy L Weigel; Dean P Edwards
Journal:  Mol Endocrinol       Date:  2009-12-11

9.  Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors.

Authors:  Emily J Faivre; Andrea R Daniel; Christopher J Hillard; Carol A Lange
Journal:  Mol Endocrinol       Date:  2008-01-17

10.  Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK.

Authors:  Lindsey S Treviño; Michael J Bolt; Sandra L Grimm; Dean P Edwards; Michael A Mancini; Nancy L Weigel
Journal:  Mol Endocrinol       Date:  2015-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.